RE:oh dearAccording to Dr. Vile the issues with checkpoint inhibitors have to do with the timing of the administration, as I have always suggested, and specific to the checkpoint inhibitor avelumab, Dr. Vile believes that Bavencio is cleared too quickly from the cell due to the Fc component, and therefore did not have the desired affect that other immune checkpoint inhibitors could offer.
Consequently, both Drs. Pratt and Vile commented that they thought that there would not be the same issues with other immune checkpoint inhibitors, such as atezolizumab and others, as there has been seen with Bavencio.